ATE312620T1 - Testverfahren für antifibrotischen wirkstoff - Google Patents

Testverfahren für antifibrotischen wirkstoff

Info

Publication number: ATE312620T1
Authority: AT; Austria
Prior art keywords: igf; culture system; fibrotic agents; tgf; beta
Prior art date: 1996-10-25

Application number

AT97949342T

Other languages

English (en)

Inventor

Jeffrey C Geesin

Anna Gosiewska

Original Assignee

Ethicon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-25

Filing date

1997-10-24

Publication date

2005-12-15

1997-10-24 Application filed by Ethicon Inc filed Critical Ethicon Inc

2005-12-15 Application granted granted Critical

2005-12-15 Publication of ATE312620T1 publication Critical patent/ATE312620T1/de

Links

230000003510 anti-fibrotic effect Effects 0.000 title abstract 4
239000004480 active ingredient Substances 0.000 title 1
238000010998 test method Methods 0.000 title 1
238000000034 method Methods 0.000 abstract 5
NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 abstract 3
239000003795 chemical substances by application Substances 0.000 abstract 3
238000003501 co-culture Methods 0.000 abstract 3
102000038460 IGF Type 2 Receptor Human genes 0.000 abstract 2
108010031792 IGF Type 2 Receptor Proteins 0.000 abstract 2
108060008539 Transglutaminase Proteins 0.000 abstract 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
238000012216 screening Methods 0.000 abstract 2
102000003601 transglutaminase Human genes 0.000 abstract 2
102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 abstract 1
108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 abstract 1
102000002938 Thrombospondin Human genes 0.000 abstract 1
108060008245 Thrombospondin Proteins 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
239000002260 anti-inflammatory agent Substances 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
230000003828 downregulation Effects 0.000 abstract 1
229960000890 hydrocortisone Drugs 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
210000002540 macrophage Anatomy 0.000 abstract 1
230000007246 mechanism Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
108020004999 messenger RNA Proteins 0.000 abstract 1
229940012957 plasmin Drugs 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Zoology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Cell Biology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Pathology (AREA)
General Chemical & Material Sciences (AREA)
Analytical Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT97949342T 1996-10-25 1997-10-24 Testverfahren für antifibrotischen wirkstoff ATE312620T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2963296P	1996-10-25	1996-10-25
PCT/US1997/019451 WO1998017304A1 (en)	1996-10-25	1997-10-24	Anti-fibrotic agent assay

Publications (1)

Publication Number	Publication Date
ATE312620T1 true ATE312620T1 (de)	2005-12-15

Family

ID=21850051

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97949342T ATE312620T1 (de)	1996-10-25	1997-10-24	Testverfahren für antifibrotischen wirkstoff

Country Status (8)

Country	Link
EP (1)	EP0956036B1 (de)
JP (1)	JP2001511885A (de)
AT (1)	ATE312620T1 (de)
AU (1)	AU740052B2 (de)
CA (1)	CA2269711A1 (de)
DE (1)	DE69734894T2 (de)
ES (1)	ES2253788T3 (de)
WO (1)	WO1998017304A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2862867A3 (de)	2005-10-25	2015-08-05	The Johns Hopkins University	Verfahren und Zusammensetzungen zur Behandlung des Marfan-Syndroms und assoziierter Erkrankungen
EP2230252A1 (de)	2006-03-13	2010-09-22	The Johns Hopkins University	Erhöhung der endothelialen Thromboresistenz
DK2083863T3 (da)	2006-10-03	2015-06-22	Genzyme Corp	Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
DK3117709T3 (en)	2010-03-12	2018-11-26	Genzyme Corp	COMBINATION THERAPY FOR TREATMENT OF BREAST CANCER
CA2823154A1 (en)	2010-12-27	2012-07-05	Lsip, Llc	Ips cells and method for generating same
EP2737083A1 (de)	2011-07-27	2014-06-04	INSERM (Institut National de la Santé et de la Recherche Scientifique)	Verfahren zur diagnose und behandlung des myhre-syndroms
WO2013062544A1 (en)	2011-10-26	2013-05-02	Seattle Children's Research Institute	Cysteamine in the treatment of fibrotic disease
EP2799537B1 (de)	2011-12-28	2021-09-22	Kyoto Prefectural Public University Corporation	Normalisierung der züchtung von hornhautendothelzellen
JPWO2015064768A1 (ja)	2013-10-31	2017-03-09	京都府公立大学法人	角膜内皮の小胞体細胞死関連疾患治療薬
WO2016187312A1 (en)	2015-05-18	2016-11-24	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods and compositions for treating an alphavirus infection
CA3141216A1 (en) *	2019-08-15	2021-02-18	Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh)	Modulating extracellular matrix movement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0466315A3 (en) *	1990-05-30	1992-07-01	Larrian Gillespie	Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
SE9101840L (sv) *	1991-06-14	1992-12-15	Kabi Pharmacia	Ny medicinsk anvaendning
US5407913A (en) *	1992-12-03	1995-04-18	Celtrix Pharmaceuticals, Inc.	Method and composition for systemic treatment of tissue injury

1997
- 1997-10-24 AT AT97949342T patent/ATE312620T1/de not_active IP Right Cessation
- 1997-10-24 ES ES97949342T patent/ES2253788T3/es not_active Expired - Lifetime
- 1997-10-24 WO PCT/US1997/019451 patent/WO1998017304A1/en active IP Right Grant
- 1997-10-24 JP JP51969898A patent/JP2001511885A/ja active Pending
- 1997-10-24 CA CA002269711A patent/CA2269711A1/en not_active Abandoned
- 1997-10-24 EP EP97949342A patent/EP0956036B1/de not_active Expired - Lifetime
- 1997-10-24 AU AU68107/98A patent/AU740052B2/en not_active Expired
- 1997-10-24 DE DE69734894T patent/DE69734894T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0956036A1 (de)	1999-11-17
EP0956036A4 (de)	2001-10-10
AU740052B2 (en)	2001-10-25
JP2001511885A (ja)	2001-08-14
AU6810798A (en)	1998-05-15
DE69734894T2 (de)	2006-07-20
CA2269711A1 (en)	1998-04-30
DE69734894D1 (de)	2006-01-19
ES2253788T3 (es)	2006-06-01
WO1998017304A1 (en)	1998-04-30
EP0956036B1 (de)	2005-12-14

Publication	Publication Date	Title
Hwang et al.	2019	Variable osteogenic performance of MC3T3-E1 subclones impacts their utility as models of osteoblast biology
Agís-Balboa et al.	2006	Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis
Shah et al.	2008	Functional significance of axonal Kv7 channels in hippocampal pyramidal neurons
Duffield et al.	2003	The tetraspanin CD63 enhances the internalization of the H, K-ATPase β-subunit
ATE312620T1 (de)	2005-12-15	Testverfahren für antifibrotischen wirkstoff
DE69841164D1 (de)	2009-10-29	Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
Ortiz et al.	2018	CD 44 and ALDH 1 immunoexpression as prognostic indicators of invasion and metastasis in oral squamous cell carcinoma
NO331148B1 (no)	2011-10-24	Anvendelse av et monoklonalt eller polyklonalt antistoff, samt fremgangsmate og kit for in vitro diagnose.
Schmidlin et al.	2002	Heterologous regulation of trafficking and signaling of G protein-coupled receptors: β-arrestin-dependent interactions between neurokinin receptors
Patte-Mensah et al.	2005	Substance P inhibits progesterone conversion to neuroactive metabolites in spinal sensory circuit: a potential component of nociception
EP0747656A3 (de)	1998-11-25	Verfahren und Vorrichtung zum Testen von Raketen
Tanaka et al.	1998	A study on epidermal proliferation ability in cholesteatoma
DE69731977D1 (de)	2005-01-20	Spezifische antikörper für dendritische zellen
BR9915055A (pt)	2001-08-07	Teste diagnóstico de tuberculose
Baker et al.	2005	Reevaluating thyrotropin receptor-induced mouse models of Graves’ disease and ophthalmopathy
Pesce et al.	2002	Glomerular cell replication and cell loss through apoptosis in experimental diabetes mellitus
Bragina et al.	2010	Heterogeneity of glutamatergic and GABAergic release machinery in cerebral cortex: analysis of synaptogyrin, vesicle-associated membrane protein, and syntaxin
Vergés et al.	1999	A tubular endosomal fraction from rat liver: biochemical evidence of receptor sorting by default
Gruenewald et al.	1991	Age-related decrease in proopiomelanocortin gene expression in the arcuate nucleus of the male rat brain
TR199700482A2 (xx)	1998-01-21	LC132 (Opioid benzeri) resept�r fonksiyonunun mod�lasyonu.
DK0782706T3 (da)	2001-03-19	Testmetode
ATE415487T1 (de)	2008-12-15	Biologisches testverfahren für thyroid stimulierende antikörper
MX9302549A (es)	1994-07-29	Proteina receptora especifica para la region csvt cg de la trombospondina y metodo para su purificacion y caracterizacion.
Jones et al.	1997	Modulation of MCF-7 cell proliferative responses by manipulation of assay conditions
GR3034891T3 (en)	2001-02-28	Method and kit for predicting the therapeutic response of a drug against a malignant tumour

Legal Events

Date	Code	Title	Description
2006-09-15	UEP	Publication of translation of european patent specification	Ref document number: 0956036 Country of ref document: EP
2008-01-15	REN	Ceased due to non-payment of the annual fee

Date

Code

Title

Description

2006-09-15

UEP

Publication of translation of european patent specification

Ref document number: 0956036

Country of ref document: EP

2008-01-15

REN

Ceased due to non-payment of the annual fee